JPH10147529A5 - - Google Patents

Info

Publication number
JPH10147529A5
JPH10147529A5 JP1997298654A JP29865497A JPH10147529A5 JP H10147529 A5 JPH10147529 A5 JP H10147529A5 JP 1997298654 A JP1997298654 A JP 1997298654A JP 29865497 A JP29865497 A JP 29865497A JP H10147529 A5 JPH10147529 A5 JP H10147529A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
effective amount
period
compound
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997298654A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10147529A (ja
Filing date
Publication date
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed filed Critical
Publication of JPH10147529A publication Critical patent/JPH10147529A/ja
Publication of JPH10147529A5 publication Critical patent/JPH10147529A5/ja
Pending legal-status Critical Current

Links

JP9298654A 1996-10-30 1997-10-30 乳癌を予防する方法 Pending JPH10147529A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
US60/029850 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10
US9624800 1997-03-10
US60/040260 1997-03-10

Publications (2)

Publication Number Publication Date
JPH10147529A JPH10147529A (ja) 1998-06-02
JPH10147529A5 true JPH10147529A5 (enExample) 2005-07-07

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9298682A Withdrawn JPH10147530A (ja) 1996-10-30 1997-10-30 乳癌の予防に関する改善
JP9298654A Pending JPH10147529A (ja) 1996-10-30 1997-10-30 乳癌を予防する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP9298682A Withdrawn JPH10147530A (ja) 1996-10-30 1997-10-30 乳癌の予防に関する改善

Country Status (43)

Country Link
US (2) US6303634B1 (enExample)
EP (3) EP0839532B1 (enExample)
JP (2) JPH10147530A (enExample)
CN (2) CN1182590A (enExample)
AP (1) AP971A (enExample)
AR (2) AR010538A1 (enExample)
AT (2) ATE338551T1 (enExample)
AU (3) AU5005697A (enExample)
BE (2) BE1011381A5 (enExample)
BG (1) BG63841B1 (enExample)
BR (1) BR9712703A (enExample)
CA (2) CA2219377A1 (enExample)
CH (2) CH693820A5 (enExample)
CZ (2) CZ341297A3 (enExample)
DE (2) DE69736644T2 (enExample)
DK (2) DK0839532T3 (enExample)
EA (2) EA006083B1 (enExample)
EE (1) EE03663B1 (enExample)
ES (4) ES2135342B1 (enExample)
FR (2) FR2755014B1 (enExample)
GB (3) GB2318733A (enExample)
GE (1) GEP20032910B (enExample)
GR (2) GR1003189B (enExample)
HU (2) HUP9701777A3 (enExample)
IE (2) IE970772A1 (enExample)
IL (2) IL122026A0 (enExample)
IS (1) IS5035A (enExample)
IT (2) ITMI972434A1 (enExample)
LU (2) LU90158B1 (enExample)
LV (1) LV12353B (enExample)
MY (1) MY121623A (enExample)
NL (2) NL1007387C2 (enExample)
NO (2) NO974973D0 (enExample)
NZ (1) NZ329042A (enExample)
PT (2) PT1369115E (enExample)
RO (1) RO120813B1 (enExample)
SG (2) SG72765A1 (enExample)
SI (3) SI0839532T1 (enExample)
SK (1) SK287047B6 (enExample)
TR (1) TR199900951T2 (enExample)
UA (1) UA46762C2 (enExample)
WO (2) WO1998018325A1 (enExample)
YU (1) YU42397A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733A7 (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
WO2025099483A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Use for raloxifene for the treatment of hepatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CA2118096A1 (en) * 1993-10-15 1995-04-16 Srinivasan Chandrasekhar Methods for treating resistant neoplasms
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
BR9500758A (pt) * 1994-03-02 1995-10-24 Lilly Co Eli Formulaçoes farmacêuticas para administraçao oral
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
MEP18308A (en) * 1996-03-26 2010-06-10 Lilly Co Eli Benzothiophenes, formulations containing same, and methods

Similar Documents

Publication Publication Date Title
JPH10147529A5 (enExample)
RU96119781A (ru) Применение 2-фенил-3-ароилбензотиофенов для снижения уровня холестерина в сыворотке, фармацевтическая композиция
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
RU2003119460A (ru) Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с
DK0503440T3 (da) Sumatriptanholdige lægemidler
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
JP2002529490A (ja) 歯牙吸収性病変の阻害方法
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
JP2005515966A5 (enExample)
JP2009102342A5 (enExample)
JPH11193282A5 (enExample)
JP2003509349A5 (enExample)
JP2001526218A5 (enExample)
RU98115774A (ru) Новые производные 19-нор-прегнена
WO1987004618A1 (en) Treatment of bone loss
JP2007520452A5 (enExample)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
RU2003105159A (ru) Способ лечения климактерических расстройств у женщин во время или после менопаузы
JP2002522501A5 (enExample)
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
RU2004131214A (ru) Способы лечения когнитивных расстройств
JP2019531286A5 (enExample)
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
JP2000026292A5 (enExample)